Question

In: Accounting

Problem 16-5 Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the...

Problem 16-5

Amy Dyken, controller at Buffalo Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Buffalo’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. BUFFALO PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,000,000 8% convertible bonds payable 5,080,000 10% bonds payable 5,940,000 Total long-term debt $12,020,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par value, 106,000 shares authorized, 26,500 shares issued and outstanding $1,325,000 Common stock, $1 par, 9,900,000 shares authorized, 990,000 shares issued and outstanding 990,000 Additional paid-in capital 3,920,000 Retained earnings 5,900,000 Total shareholders’ equity $12,135,000 The following transactions have also occurred at Buffalo.

1. Options were granted on July 1, 2016, to purchase 220,000 shares at $15 per share. Although no options were exercised during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share.

2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016

3. The preferred stock was issued in 2016. 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017. 5. The 990,000 shares of common stock were outstanding for the entire 2017 fiscal year. 6. Net income for fiscal year 2017 was $1,520,000, and the average income tax rate is 40%. For the fiscal year ended June 30, 2017, calculate the following for Buffalo Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.) (a) Basic earnings per share. Basic earnings per share $ (b) Diluted earnings per share. Diluted earnings per share $

Solutions

Expert Solution

a) ans:-
Choose Numerator / Choose Denominator = Basic Earning Per Share
Net Income - Preferred Dividends / Weighted Average Shares Basic Earning Per Share
$             1,520,000.00 - (26,500*$50*6%) / 990,000 =
$             1,520,000.00 - $79,500 / 990,000 = 1.45
b)
Net Income $      1,520,000.00
Less: Preferred Dividen(26,500*$50*6%) $            79,500.00
Add: Interest ( Net of Tax) $          243,840.00
(5,080,000*8%*(1-40%))
$      1,684,340.00
Outstanding Shares 990,000
Convertible Bonds(5,080,000*50/1000) 254,000
Incremental Shares Options 55,000
220,000(20-15)/20
Average Shares 1,299,000

Diluted earnings per share =$1,684,340/1,299,000= $1.29


Related Solutions

Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Kingbird Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Kingbird’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. KINGBIRD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 9% $1,000,000 8% convertible bonds payable 4,910,000 9% bonds payable 6,080,000 Total long-term debt $11,990,000 Shareholders’ equity Preferred stock, 7% cumulative,...
Problem 16-5 Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the...
Problem 16-5 Amy Dyken, controller at Ivanhoe Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Ivanhoe’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. IVANHOE PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt    Notes payable, 11% $1,010,000    8% convertible bonds payable 5,050,000    11% bonds payable 5,950,000      Total long-term debt $12,010,000 Shareholders’ equity    Preferred stock, 6% cumulative,...
Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sheridan Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,090,000 10% bonds payable 6,060,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $980,000    8% convertible bonds payable 5,030,000    11% bonds payable 6,100,000      Total long-term debt $12,110,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Waterway Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt       Notes payable, 10% $990,000 8% convertible bonds payable       5,030,000 10% bonds payable 5,880,000 Total long-term debt $11,900,000         Shareholders’ equity       Preferred...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the...
Question 4 Amy Dyken, controller at Marigold Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Marigold’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Marigold Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative,...
Problem 1: A company is going public at $16 and will use the ticker XYZ. The...
Problem 1: A company is going public at $16 and will use the ticker XYZ. The underwriters will charge a 7 percent spread. The company is issuing 20 million shares, and insiders will continue to hold an additional 40 million shares that will not be part of the IPO. The company will also pay $1 million of audit fees, $2 million of legal fees, and $500,000 of printing fees. The stock closes the first day at $19. The company in...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing...
Eye Trendy Corporation is a distributor of frames for sunglasses. The company’s controller is currently preparing a budget for the third quarter of the year. The following information is from company’s financial records: Projected Sales July 3,120 units August 2,000 units September 2,640 units October 3,000 units • Selling price is RM25 per unit • Collections from customers are normally 70 per cent in the month of sale, 20 per cent in the month following sale, and 9 per cent...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It...
Oman Pharmaceutical Industries Co. (OPP) is one of the fastest growing pharmaceutical company in GCC. It manufactures four joint products Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin from a chemical process. After further processing, the company sells Azithromycin, Clarithromycin, Levofloxacin and Moxifloxacin at a price of RO 20, RO 24, RO 16 and RO 12 and estimates a profit of 17.5%, 12.5%, 12.5% and 15% respectively. The costs incurred till the split- off point are RO 39,000. The output achieved at the...
Problem 8-3 Some of the transactions of Buffalo Company during August are listed below. Buffalo uses...
Problem 8-3 Some of the transactions of Buffalo Company during August are listed below. Buffalo uses the periodic inventory method. August 10 Purchased merchandise on account, $13,600, terms 2/10, n/30. 13 Returned part of the purchase of August 10, $1,200, and received credit on account. 15 Purchased merchandise on account, $16,800, terms 1/10, n/60. 25 Purchased merchandise on account, $21,600, terms 2/10, n/30. 28 Paid invoice of August 15 in full. Assuming that purchases are recorded at gross amounts and...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT